Beam Therapeutics (BEAM) versus Its Competitors Head to Head Comparison

Beam Therapeutics (NASDAQ:BEAM) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Beam Therapeutics to similar businesses based on the strength of its valuation, profitability, institutional ownership, earnings, risk, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for Beam Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1	2	9	1	2.77
Beam Therapeutics Competitors	9869	15283	45611	1598	2.54

Beam Therapeutics presently has a consensus target price of $47.64, suggesting a potential upside of 91.16%. As a group, “Biotechnology” companies have a potential upside of 123.18%. Given Beam Therapeutics’ competitors higher possible upside, analysts plainly believe Beam Therapeutics has less favorable growth aspects than its competitors.

Volatility and Risk

Beam Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Comparatively, Beam Therapeutics’ competitors have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Valuation & Earnings

This table compares Beam Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beam Therapeutics	$139.74 million	-$79.99 million	-23.96
Beam Therapeutics Competitors	$756.66 million	$13.58 million	-18.98

Beam Therapeutics’ competitors have higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Beam Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-73.04%	-32.76%	-25.80%
Beam Therapeutics Competitors	-12,323.33%	-195.38%	-30.39%

Institutional and Insider Ownership

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Beam Therapeutics beats its competitors on 8 of the 13 factors compared.

Beam Therapeutics Company Profile

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.